AAM Applauds CMS for Requiring Health Plans to Place Generic Drugs On Generic Tiers
WASHINGTON, DC (January 30, 2023) — The Association for Accessible Medicines (AAM) applauds the Centers for Medicare & Medicaid Services (CMS) for several of the recommended provisions outlined in the proposed Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024. In particular, AAM publicly commends the administration’s efforts to standardize […]
Ensuring Patient Access to Amoxicillin When Demand is High
The Facts About the Generic Supply and Production of Antibiotics Used to Treat Flu, RSV and COVID Families and physicians in certain parts of the country are finding it difficult to access commonly prescribed medicines, such as amoxicillin, this winter. The combination of widespread influenza, respiratory syncytial virus (RSV) and COVID infections – in what […]
AAM Statement on the Consolidated Appropriations Act of 2023
WASHINGTON, D.C. (December 20, 2022) – The Association for Accessible Medicines Interim President, David Gaugh, today released the following statement regarding the Consolidated Appropriations Act of 2023. “The Consolidated Appropriations Act of 2023 includes critical improvements to help facilitate the development of generic and biosimilar medicines and takes steps to enhance the security of the […]
AAM Statement on CMS’s Proposed Rule Requiring Generic Drugs to be Covered on Generic Tiers
WASHINGTON D.C. (December 13, 2022) — The Association for Accessible Medicines (AAM) commends the Centers for Medicare & Medicaid Services (CMS) for their proposal requiring generic drugs to be covered on generic tiers. “This common-sense approach will result in meaningful savings for America’s patients,” said David Gaugh, Interim CEO of AAM. “As CMS notes, ‘it is reasonable to assume […]
AAM Statement on the Centers for Medicare & Medicaid Services’ Implementation of Medicare Part B Payment Changes for Biosimilars
WASHINGTON D.C. (October 3, 2022) — The Association for Accessible Medicines (AAM) and its Biosimilars Council applaud the Centers for Medicare & Medicaid Services for its support of biosimilars and rapid implementation of the enhanced payment for biosimilars in Medicare Part B. “Biosimilars are providing greater access to patients at lower costs,” said Craig Burton, […]
AAM Statement on Senate Passage of Inflation Reduction Act
WASHINGTON, D.C. (August 7, 2022) – The members of the Association for Accessible Medicines (AAM) and the Biosimilars Council are extremely disappointed by the Senate’s passage of legislation that will further frustrate patient access to safe, affordable generic and biosimilar medicines. The Senate has chosen to replace competition – the only proven way to provide patients […]
AAM All Access Podcast: Medicare Drug Price Negotiation is Bad for Patients
Three Experts Weigh In AAM’s All Access Podcast lets us all learn from leaders and influential figures in health care. This series of candid, wide-ranging dialogues has given me a deeper appreciation of the dedication and brilliance of the men and women who take on the challenge of making prescription medicines more widely accessible. Only […]
Medicare Negotiations Serve as a Catalyst to a Perpetual Monopolyc
Generic medicines offer proven cost savings for America’s seniors and taxpayers, more than $2 trillion over the past 10 years alone. This is the result of robust head-to-head price competition under which multiple generic drug makers fight for market share based on dramatically lower prices. Despite this successful track record, lawmakers in Congress are proposing […]
AAM Statement on BBB 2.0
This flawed, untested scheme will reduce future savings through lower cost generic and biosimilar medicines for America’s patients and employers. The Build Back Better Act’s negotiations framework severely erodes the incentives for generic and biosimilar development. Generic and biosimilar manufacturers will be less likely to incur the costs and risks associated with developing new generic […]
Challenges & Solutions for Prescription Drug Savings Identified by MedPAC
As policymakers seek to respond to concerns about high drug costs, a recent report may provide a path forward. The Medicare Payment Advisory Commission (MedPAC) provides independent expert advice to Congress on Medicare payment policies and in a recent report to Congress, it recommends key changes to the Part D program that could serve as […]
Avalere Analysis Finds Medicare Part D Patients Continue to Pay More for Generics
WASHINGTON D.C. (January 24, 2022) –Avalere’s recent findings add to the growing body of evidence that Medicare Part D Plans are preventing patients from realizing the full value of low-cost generic drugs. For the third year in a row, fewer than half of all generic drugs are on generic formulary tiers, even as generic prices […]
Generic Prices Are Falling, But Seniors Are Paying More for Generic Drugs. What’s Happening Here?
Something is wrong when America’s patients pay the same or more for an FDA-approved generic version of a high-priced brand drug. It’s even worse when those costs go up each year. Generics provide competition for expensive brand drugs and savings for patients. In 2020 alone, generics and biosimilars have saved the Medicare program $109.6 billion.1 […]
